# US 2024/0277794 A1 · Oncolytic viruses for modified mhc expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0277794 A1
- Document ID: US20240277794A1
- Status: Published application
- Kind: A1
- Application number: 18/639,303
- Filed: 2024-04-18
- Published: 2024-08-22
- Earliest claimed: 2021-04-30
- Assignees: KaliVir Immunotherapeutics, Inc.
- Applicants: KaliVir Immunotherapeutics, Inc.
- Inventors: Stephen Howard THORNE; Mingrui ZHANG
- Web page: https://patentgrep.com/patent/US20240277794A1

## CPC

- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/005: from viruses
- C07K 14/065: Poxviridae, e.g. avipoxvirus
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/86: Viral vectors
- C12N 2710/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.

## Claims

### Claim 1

A composition, wherein the composition comprises:
an oncolytic virus, wherein the oncolytic virus comprises a genome modification,
wherein the genome modification comprises an exogenous nucleic acid encoding for an MHC I inhibitor, wherein the MHC I inhibitor comprises dominant negative interferon regulator factor 7 (dnIRF7).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the dnIRF7 comprises an amino acid sequence of SEQ ID NO: 37.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the exogenous nucleic acid encoding for the MHC I inhibitor comprises a nucleic acid sequence of SEQ ID NO: 36.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the exogenous nucleic acid encoding for an MHC I inhibitor is inserted into a genome of the oncolytic virus.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the exogenous nucleic acid encoding for an MHC I inhibitor is inserted into a locus of a thymidine kinase gene.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the genome modification further comprises:
a deletion or functional deletion of an endogenous nucleic acid encoding an MHC II inhibitor; or
an exogenous nucleic acid that results in activation or enhanced activation of MHC II presentation.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the deletion or functional deletion of the endogenous nucleic acid encoding the MHC II inhibitor comprises a deletion or functional deletion of a vaccinia virus gene encoding protein A35.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the deletion or functional deletion of the vaccinia virus gene encoding protein A35 is a deletion or functional deletion of gene WR158.

### Claim 9 (depends on 6)

The composition of claim 6, wherein the exogenous nucleic acid that results in activation or enhanced activation of the MHC II presentation encodes for a protein selected from:
a) an apoptosis inhibitor protein;
b) a necrotic cell death activator protein;
c) an autophagy enhancer protein;
d) an asparaginyl endopeptidase;
e) a class II transactivator;
f) an interferon-gamma;
g) a Toll-like receptor activator; or
h) a dendritic cell maturation activator.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the exogenous nucleic acid that results in activation or enhanced activation of MHC II presentation encodes for the autophagy enhancer protein, and wherein the autophagy enhancer protein is HMGB1 or a functional domain or a variant thereof.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the exogenous nucleic acid that results in activation or enhanced activation of MHC II presentation encodes for the dendritic cell maturation activator, wherein the dendritic cell maturation activator comprises osteopontin, TNF-alpha, or a functional fragment or variant thereof.

### Claim 12 (depends on 9)

The composition of claim 9, wherein the protein encoded by the exogenous nucleic acid is fused to a secretion sequence, a cell permeabilizing domain, or a combination thereof.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the oncolytic virus comprises a poxvirus, an adeno associated virus, an adenovirus, Newcastle disease virus (NDV), Reovirus (RV), mengovirus, Myxoma virus (MYXV), Measles virus (MV), Herpes Simplex virus (HSV), Vaccinia virus (VV), Vesicular Stomatitis virus (VSV), and Polio virus (PV).

### Claim 14 (depends on 13)

The composition of claim 13, wherein the poxvirus comprises a betaentomopoxvirus, a yatapoxvirus, a cervidpoxvirus, a gammaentomopoxvirus, a leporipoxvirus, a suipoxvirus, a molluscipoxvirus, a crocodylidpoxvirus, an alphaentomopoxvirus, a capripoxvirus, an avipoxvirus, or a parapoxvirus.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the oncolytic virus is a vaccinia virus.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the MHC I inhibitor causes an inhibition or partial inhibition of MHC I presentation.

### Claim 17 (depends on 1)

The composition of claim 1, wherein the genome modification reduces an immune response targeting a virus-infected tumor cell and increases an immune response targeting cells surrounding the virus-infected tumor cell.

### Claim 18 (depends on 1)

The composition of claim 1, wherein the genome modification further comprises mutation or a complete or a partial deletion of a viral gene comprising at least one of: A52R, B15R, K7R, A46R, NIL, E3L, K1L, M2L, C16, N2R, B8R, B18R, or VH1 of a vaccinia virus or a functional domain or fragment or variant thereof, or any combinations thereof.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the genome modification further comprises a deletion of a thymidine kinase gene.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the oncolytic virus is a vaccinia virus, and the vaccinia virus is a Western Reserve strain Vaccinia virus (ATCC VR-1354), a Copenhagen strain, an IHD strain, a Wyeth strain (ATCC VR-325), a NYCBOH strain, a Tian Tan strain, a Lister strain, an Ankara strain (ATCC VR-1508 or ATTC VR1566), a USSR strain, or an ACAM2000 strain.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising the composition according claim 1 and a pharmaceutically acceptable excipient.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the excipient comprises one or more of a buffering agent, a stabilizer, an antioxidant, a binder, a diluent, a dispersing agent, a rate controlling agent, a lubricant, a glidant, a disintegrant, a plasticizer, a preservative, or any combinations thereof.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein the excipient comprises di-sodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, myo-inositol, sorbitol, or any combinations thereof.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein the pharmaceutical composition does not comprise a preservative.

### Claim 25 (depends on 21)

The pharmaceutical composition of claim 21, further comprising one or more of a preservative, a diluent, and a carrier.

### Claim 26 (depends on 21)

The pharmaceutical composition of claim 21, further comprising an additional active ingredient or a salt thereof.

### Claim 27 (depends on 21)

The pharmaceutical composition of claim 21, wherein the excipient is sterile water.

### Claim 28 (depends on 21)

The pharmaceutical composition of claim 21, further comprising an additional active ingredient, wherein the additional active ingredient is an anti-cancer agent or a further oncolytic virus.
